Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,530 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Choice Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

NCT02306876
View directory record Official record
Conditions
Healthy
Interventions
PF-06412562 3mg BID, PF-06412562 15mg BID, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Arcadia, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

NCT07226817
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Phase 3 Interventional

REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

NCT06399692
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
18
States / cities
Glendale, California • Atlanta, Georgia • Carmel, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jun 26, 2026, 4:05 PM EDT
Active, not recruiting Phase 3 Interventional

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

NCT03769506
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Combination Product · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Jun 26, 2026, 4:05 PM EDT
Not listed No phase listed Observational

PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

NCT06390709
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Collection Only
Other
Lead sponsor
Scipher Medicine
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jun 26, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Aripiprazole Effects on Alcohol Reactivity and Consumption

NCT00183235
View directory record Official record
Conditions
Alcohol Dependence
Interventions
aripiprazole (up to 15 mg/day) for 8 days
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Jun 26, 2026, 4:05 PM EDT
Completed Early Phase 1 Interventional

Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer

NCT01725048
View directory record Official record
Conditions
Major Depressive Disorder, Neoplasms
Interventions
Mirtazapine, Citalopram
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633
View directory record Official record
Conditions
Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
[18F]FPyQCP
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

NCT02360319
View directory record Official record
Conditions
Schizophrenia
Interventions
Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 35 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
39
States / cities
Tucson, Arizona • Granada Hills, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

NCT07558733
View directory record Official record
Conditions
HR+ HER2- Breast Cancer
Interventions
Serabelisib, Sapanisertib, Fulvestrant
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Los Angeles, California • Springfield, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

NCT02205333
View directory record Official record
Conditions
Advanced Solid Tumors, Aggressive B-cell Lymphomas
Interventions
MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab, MEDI6469 Plus Durvalumab, MEDI6469 plus Rituximab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jun 26, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AFib Stroke Prevention

NCT04096781
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Cardiac, Heart Failure, Arrhythmia
Interventions
SDMT, Usual Care
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Palo Alto, California • New Orleans, Louisiana • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Jun 26, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Optimize RV Selective Site Pacing Clinical Trial

NCT00422669
View directory record Official record
Conditions
Cardiac Pacing, Artificial, Cardiac Pacemaker, Artificial
Interventions
Medtronic Dual-Chamber Pacemaker, Medtronic SelectSecure 3830 Lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
16
States / cities
Bridgeport, Connecticut • Clearwater, Florida • Hudson, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jun 26, 2026, 4:05 PM EDT
Withdrawn Not applicable Interventional

3M Veraflo™ Cleanse Choice Complete™ (VFCCC) Clinical Study

NCT05748392
View directory record Official record
Conditions
WOUNDS INJURIES
Interventions
Wound and per-wound assessments While using Device
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jun 26, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

NCT03152526
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Interventions
Device
Lead sponsor
Miltenyi Biotec B.V. & Co. KG
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of Neurodegenerative Disorders

NCT03333200
View directory record Official record
Conditions
MLD, Krabbe Disease, ALD, MPS I, MPS II, MPS III, Vanishing White Matter Disease, GM3 Gangliosidosis, PKAN, Tay-Sachs Disease, NP Deficiency, Osteopetrosis, Alpha-Mannosidosis, Sandhoff Disease, Niemann-Pick Diseases, MPS IV, Gaucher Disease, GAN, GM1 Gangliosidoses, Morquio Disease, S-Adenosylhomocysteine Hydrolase Deficiency, Batten Disease, Pelizaeus-Merzbacher Disease, Leukodystrophy, Lysosomal Storage Diseases, Purine Nucleoside Phosphorylase Deficiency, Multiple Sulfatase Deficiency Disease
Interventions
Palliative Care, Hematopoetic Stem Cell Transplantation
Other · Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions
STK-012, pembrolizumab, pemetrexed, carboplatin
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes

NCT06382636
View directory record Official record
Conditions
Prenatal Disorder
Interventions
Standard Care, Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 26, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

NCT04469764
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Abemaciclib, Anastrozole, Letrozole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 26, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Physical Activity Choices Everyday- A Pilot Study

NCT03843099
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Weight Loss + Future Thinking, Behavioral Weight Loss + Healthy Thinking
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jun 26, 2026, 4:05 PM EDT
Completed No phase listed Observational

C.Difficile Observational Study

NCT06277999
View directory record Official record
Conditions
Clostridium Infections
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Sacramento, California • Hamden, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 26, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Safer Choices 2 - HIV, STD, & Pregnancy Prevention Program

NCT00223314
View directory record Official record
Conditions
HIV, Sexually Transmitted Diseases, Pregnancy, HIV Infections
Interventions
HIV, STD, Pregnancy Prevention Curriculum
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Jun 26, 2026, 4:05 PM EDT